SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a)
AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)
(Amendment No. 1)
AVATEX CORPORATION
-------------
(Name of Issuer)
Common Stock
-----------------------------
(Title of Class of Securities)
05349F105
---------
(CUSIP Number)
Morris F. DeFeo, Jr.
Swidler & Berlin, Chartered
3000 K Street, N.W., Suite 300
Washington, D.C. 20007
(202) 424-7500
---------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
April 20, 1998
---------------
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the
following box [ ].
NOTE. Six copies of this statement, including all exhibits, should be
filed with the Commission. See Rule 13d-7(b) for other parties to whom copies
are to be sent.
(Continued on following pages)
(Page 1 of 4 Pages)<PAGE>
<PAGE>
SCHEDULE 13D/A
- ------------------------ -----------------------
CUSIP No. 05349F105 Page 2 of 4 Pages
- ------------------------ -----------------------
- --------------------------------------------------------------------------
1. NAMES OF REPORTING PERSONS: Phar-Mor, Inc.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): 251466309
- ---------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [ ]
- ---------------------------------------------------------------------------
3. SEC USE ONLY
- ----------------------------------------------------------------------------
4. SOURCE OF FUNDS WC
- -----------------------------------------------------------------------------
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2(d) or 2(e) [ ]
- ------------------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION Pennsylvania
- ------------------------------------------------------------------------------
NUMBER OF 7. SOLE VOTING POWER: 1,366,300
SHARES BENEFICIALLY ------------------------------------------------------
OWNED BY EACH 8. SHARED VOTING POWER: 0
REPORTING --------------------------------------------------------
PERSON 9. SOLE DISPOSITIVE POWER: 1,366,300
WITH --------------------------------------------------------
10. SHARED DISPOSITIVE POWER: 0
- ------------------------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,366,300
- -----------------------------------------------------------------------------
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES [ ]
- -----------------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.90%
- ----------------------------------------------------------------------------
14. TYPE OF REPORTING PERSON* CO
- -----------------------------------------------------------------------------
This Amendment No. 1 ("Amendment No. 1") to Schedule 13D filed by Phar-Mor,
Inc., a Pennsylvania corporation ("Phar-Mor"), with respect to the common
stock, par value $5.00 per share (the "Common Shares"), of Avatex Corporation,
a Delaware corporation (the "Issuer"), amends and/or supplements, as
indicated, Items 3, 5 and 6 of the Schedule 13D filed by Phar-Mor on May 4,
1998 (the "Statement").
<PAGE>
<PAGE>
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
Phar-Mor purchased a total of 174,600 Common Shares between
May 6, 1998 and May 27, 1998 on the New York Stock Exchange as follows:
Date Number of Shares Price per Common Share
---- ---------------- ----------------------
05/06/98 4,300 $2.3125
05/18/98 80,000 2.1734
05/19/98 9,100 2.3125
05/20/98 50,600 2.3118
05/21/98 11,800 2.2500
05/22/98 7,700 2.2500
05/27/98 11,100 2.1982
Total: 174,600
All of the funds used to purchase the above-mentioned 174,600 Common Shares
were from Phar-Mor's general corporate funds.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
(a) The aggregate number of Common Shares beneficially owned by Phar-
Mor is 1,366,300 shares, constituting 9.90% of the Issuer's Common Shares
issued and outstanding (based on 13,806,375 Common Shares outstanding based
upon the Issuer's Quarterly Report on Form 10-Q filed with the U.S. Securities
and Exchange Commission on February 4, 1998.)
(b) Phar-Mor has the sole power to vote, to direct the vote of, and to
dispose and to direct the disposition of, 1,366,300 Common Shares of the
Issuer.
(c) Since the filing of the Statement, Phar-Mor purchased a total of
174,600 Common Shares of the Issuer, as reported in Item 3 above.
(d) No other person is known to have the right to receive or the power
to direct the receipt of dividends from, or the proceeds from the sale of,
such securities.
(e) Not applicable.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH
RESPECT TO SECURITIES OF THE ISSUER
Phar-Mor does not have any contract, arrangement, understanding or
relationship (legal or otherwise) with any person with respect to any
securities of the Issuer, including but not limited to the transfer of any of
the Common Shares beneficially owned by Phar-Mor, finder's fees, joint
ventures, guarantees of profits, division of profits or loss, or the giving or
withholding of proxies.
Page 3 of 4<PAGE>
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: May 28, 1998
PHAR-MOR, INC.
By: /s/ John R. Ficarro
---------------------------------
Name: John R. Ficarro
-------------------------------
Title: Chief Administrative Officer
-------------------------------
Page 4 of 4
